| Bioactivity | CGP-53353 (DAPH-7) is an potent PKC inhibitor with IC50s of 0.41 mM and 3.8 mM for PKCβII and PKCβI, respectively. CGP-53353 can inhibit glucose-induced cell proliferation and DNA synthesis in AoSMC and A10 cells. CGP-53353 can be used for researching atherosclerosis of diabetic patients[1]. | ||||||||||||
| Invitro | CGP-53353 (DAPH-7) (1 μM; 48-96 hours) inhibits glucose-induced cell proliferation in A10 cells[1].CGP-53353 (1 μM ; 0-48 hours) inhibits the glucose-induced increase and acceleration of DNA synthesis in A10, also blocks the glucose-induced increase of S-phase cell percentage[1]. Cell Proliferation Assay Cell Line: | ||||||||||||
| Name | CGP-53353 | ||||||||||||
| CAS | 145915-60-2 | ||||||||||||
| Formula | C20H13F2N3O2 | ||||||||||||
| Molar Mass | 365.33 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Yamamoto M, et al. Acute glucose-induced downregulation of PKC-betaII accelerates cultured VSMC proliferation. Am J Physiol Cell Physiol. 2000;279(3):C587-C595. |
CGP-53353
CAS: 145915-60-2 F: C20H13F2N3O2 W: 365.33
CGP-53353 (DAPH-7) is an potent PKC inhibitor with IC50s of 0.41 mM and 3.8 mM for PKCβII and PKCβI, respectively. CGP
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.